SPK Acquisition Corp. (NASDAQ:SPK) announced in an 8-K this morning that it has terminated its combination agreement with Varian Bio and will instead liquidate on December 29.
The SPAC did not make a required $50,000 contribution to trust on December 10 to extend its transaction deadline and on December 21 gave notice that it would terminate the merger, citing breaches by Varian of one or more of the deal’s terms.
Without the extension payment, SPK was required to liquidate as soon as practicable. It has not yet released an official redemption rate, but it is estimated to have $10.41 per share in its trust.
An earlier extension vote on September 9 saw 79.6% of its shares redeemed, whittling its trust down to about $10.8 million. SPK was only required to maintain more than $5 million in cash available to meet the deal’s conditions, but the combination had already been pending for more than 10 months since its announcement on February 14.
Westport, Connecticut-based Varian Bio is developing two novel therapeutics using aPKCi inhibitors to attempt to impede tumor growth in basal cell carcinomas, the most common cancer type in the world.
This had already been a long road from SPK’s IPO on June 8, 2021 with a nine-month initial clock. This may not mark the end of the story as the transaction stipulates that if the deal was terminated as the result of a breach by either party, that side would owe the other a $2.2 million breakup fee.
Nonetheless, the liquidation is set to occur at the close of business on December 29, with all of SPK’s rights expiring worthless.
Terms Tracker for the Week Ending November 24, 2023 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. This being the Thanksgiving holiday week, we are thankful for a lot of things, but mostly that 2023 is almost over. It’s been a rough...
At the SPAC of Dawn Though perhaps stuffed to the brim, SPAC activity continues this Thanksgiving Friday with votes by Clean Earth and Zalatoris to extend a deadline and amend trust contributions, respectively. At least seven de-SPACs are also reporting earnings today and will do so going into a futures market that is mostly green...
IB Acquisition Corp. submitted its S-1 filing Friday afternoon for a $100 million IPO, coming right on the heels of Bayview Acquisition Corp, which also filed its S-1 that day. IB is also similar to Bayview in that its units do not feature a warrant but include 1 right for 1/10. However, its trust is slightly...
Integrated Wellness (NYSE:WEL) announced in an 8-K filing that it agreed to transfer control of its sponsor to Sriram Associates, which will now take on the SPAC’s financial obligations and may appoint a new team. Sriram is acquiring 2,012,500 promote shares (70%) and 4,795,000 private placement warrants (70%) for the nominal purchase price of $1....
At the SPAC of Dawn So far, seven SPACs have announced their liquidations this week and although some others may choose to use the holiday to quietly disband, this tends to be a positive week for equities in general. Going back to 1961, the S&P 500 has ended the Thanksgiving week with gains three-quarters of...